Abstract
This article presents six new [Pt(S2CNR2)Cl(PAr3)] complexes that offer phenanthriplatin type axial protection, a feature making them more active than cisplatin against three cancer cell lines (LU, MCF7 and Hepa-1c1c7). The DNA-binding, denaturing and cleavage studies revealed that these complexes can cleave DNA through complex-DNA adduct formation. Complexes have the potential to form mono-cationic species, [Pt(S2CNR2)(PAr3)]+, as manifested by DFT and chloride substitution studies. These axially protected mono-cationic complexes may safely reach the critical target DNA arresting its replication, ultimately growth of cancer cell, through monofunctional adduct formation with DNA.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
